bioAffinity Technologies

CyPath Lung optimization boosts data acquisition throughput by 50% and reduces sample processing costs by 60%. The recent enhancements streamline lab processing and data acquisition workflows, reduce reagent usage, and cut laboratory supply costs—all without changing the test itself, how patient sputum samples are collected and processed, or the method by which data is acquired and analyzed. The improvements are expected to result in a greater than 10% increase in overall throughput and a greater than 25% decrease in unit cost. 🔗 Read the full press release: https://bit.ly/bioAffTech #CyPathLung #EarlyDetection #LungCancer #Biotech #Innovation #bioAffinityTechnologies

CyPath Lung optimization boosts data acquisition throughput by 50% and reduces sample processing costs by 60%. The recent enhancements streamline lab processing and data acquisition workflows, reduce reagent usage, and cut laboratory supply costs—all without changing the test itself, how patient sputum samples are collected and processed, or the method by which data is acquired and analyzed. The improvements are expected to result in a greater than 10% increase in overall throughput and a greater than 25% decrease in unit cost. 🔗 Read the full press release: https://bit.ly/bioAffTech #CyPathLung #EarlyDetection #LungCancer #Biotech #Innovation #bioAffinityTechnologies

CyPath Lung optimization boosts data acquisition throughput by 50% and reduces sample processing costs by 60%. The recent enhancements streamline lab processing and data acquisition workflows, reduce reagent usage, and cut laboratory supply costs—all without changing the test itself, how patient sputum samples are collected and processed, or the method by which data is acquired and analyzed. The improvements are expected to result in a greater than 10% increase in overall throughput and a greater than 25% decrease in unit cost. 🔗 Read the full press release: https://bit.ly/bioAffTech #CyPathLung #EarlyDetection #LungCancer #Biotech #Innovation #bioAffinityTechnologies

Late-stage lung cancer diagnoses remain a significant challenge—It’s not just statistics, it’s personal. At bioAffinity Technologies, our journey began with a mission to change the narrative. We developed CyPath® Lung, a non-invasive test designed to detect lung cancer at its earliest stages, when treatment is most effective. Our commitment is rooted in personal experiences and the stories of those affected by late-stage diagnoses. We believe in a future where early detection is the norm, not the exception. Learn more about our story and how we are striving to make a difference. #CyPathLung #LungCancer #EarlyDetectionSavesLives #bioAfffinityTechnologies

Did you know lung cancer causes more deaths each year than breast, prostate, and colon cancer combined? According to the American Cancer Society, over 234,000 new cases of lung cancer will be diagnosed in the U.S. this year—and nearly 127,000 people will die from it. The survival rate drastically improves when lung cancer is caught early, but unfortunately, most cases aren’t diagnosed until later stages. That’s why CyPath® Lung is such a breakthrough. The non-invasive test uses flow cytometry and AI to analyze sputum samples to help detect lung cancer at earlier, more treatable stages, especially in high-risk patients. If you or someone you love is a smoker, former smoker, or has other risk factors, talk to your doctor about CyPath® Lung. It could make all the difference. #CyPathLung #LungCancer #EarlyDetectionSavesLives #LungCancerAwareness

We’re proud to stand with the American Lung Association at this year’s LUNG FORCE Walk—a powerful event raising awareness and support for those affected by lung cancer and lung disease. CyPath®Lung is advancing non-invasive early detection solutions that help identify lung cancer at its most treatable stage. It’s our mission to empower providers and patients with better tools—and more time. Together we’re taking steps toward a future with healthier lungs and longer lives.   #CyPathLung #LungHealth #LungNodule #HealthcareInnovation #LUNGFORCE #EarlyDetection #AmericanLungAssociation 

CyPath® Lung provided real-time information that suspicious nodules in a patient with Stage IA NSCCA were likely due to recurrence or a new cancer. A follow-up PET scan and liver biopsy confirmed ES-SCLC as a second primary cancer. Explore the full case study to learn more about how Cypath® Lung supports informed clinical decision-making: https://bit.ly/4iaw1AE #CyPathLung #lunghealth #lungnodule #HealthcareInnovation

#CyPathLung #NationalDoctorsDay #bioAffinityTech #lungcancer #thankyou

bioAffinity Technologies President and CEO Maria Zannes will be interviewed on RedChip’s Small Stocks Big Money™ show on Bloomberg TV this Saturday, March 29, 2025, at 7 p.m. ET. If you miss the interview, it can be viewed at https://bit.ly/4cdK2vW. She will discuss bioAffinity Technologies’ innovative contributions to lung health and cancer diagnostics. #BIAF #lungcancer #CyPathLung #Bloomberg #RedChip

CyPath® Lung provided key diagnostic insight for an 85-year-old patient at extremely high risk with significant smoking history, COPD, and asbestos exposure. The test result of “Unlikely Lung Cancer” avoided a risky biopsy. After three months, all nodules had resolved. Explore the full case study to learn more about how CyPath® Lung supports informed clinical decision-making: https://bit.ly/4bNzZO6 #CyPathLung #lunghealth #lungnodule #HealthcareInnovation